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ABSTRACT Antimicrobial lock solutions are important for prevention of microbial
colonization and infection of long-term central venous catheters. We investigated
the efficacy and safety of a novel antibiotic-free lock solution formed from gas
plasma-activated disinfectant (PAD). Using a luminal biofilm model, viable cells of
methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas
aeruginosa, and Candida albicans in mature biofilms were reduced by 6 to 8 orders
of magnitude with a PAD lock for 60 min. Subsequent 24-h incubation of PAD-
treated samples resulted in no detectable regrowth of viable bacteria or fungi. As a
comparison, the use of a minocycline-EDTA-ethanol lock solution for 60 min led to
regrowth of bacteria and fungi, up to 107 to 109 CFU/ml, in 24 h. The PAD lock solu-
tion had minimal impact on human umbilical vein endothelial cell viability, whereas
the minocycline-EDTA-ethanol solution elicited cell death in nearly half of human
endothelial cells. Additionally, PAD treatment caused little topological change to
catheter materials. In conclusion, PAD represents a novel antibiotic-free, noncyto-
toxic lock solution that elicits rapid and broad-spectrum eradication of biofilm-laden
microbes and shows promise for the prevention and treatment of intravascular cath-
eter infections.
KEYWORDS gas plasma-activated disinfectant, catheter, lock solution, central venous
catheter, central line-associated bloodstream infection
Central venous catheters (CVCs) provide long-term access to medication and totalparenteral nutrition for cancer, hemodialysis, short-gut, and transplant patients.
The majority of bloodstream infections in long-term CVCs (10 days) are associated
with intraluminal microbial colonization (1, 2). Current management guidelines for
catheter-related bloodstream infections (CRBSIs) recommend use of antimicrobial lock
therapy (ALT) for catheter salvage (3). Even with antibiotics at concentrations 1,000-fold
above the systemic therapeutic dose, current ALT may be ineffective in eradicating
mature bacterial and fungal biofilms (4–7). In addition, leakage of antimicrobial lock
solutions into the bloodstream has been implicated in systemic toxicity in patients with
long-term CVCs, potential for increased biofilm formation, and adverse effects on
catheter integrity and intraluminal precipitation (5, 6, 8, 9).
After 3 decades of optimizing their utility in catheter lock solutions, reliance on
current antibiotics is fundamentally challenged by the limited scope to improve the
trade-off between efficacy and toxicity (6, 7, 10) and by the potential risk of antimi-
crobial resistance (11). This has motivated a considerable number of studies of antimi-
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crobial properties of low-temperature gas plasma over the past 20 years (12–14).
Known as the 4th state of matter after solid, liquid, and gas, gas plasma is formed by
supplying a gas with sufficient energy (e.g., a high-voltage pulse) for its ionization (13).
Gas plasma contains diverse reactive oxygen species and reactive nitrogen species (ROS
and RNS, or RONS) as well as other effectors (e.g., transient charges), all changing
dynamically (12–15). Antimicrobial properties of gas plasma and also gas plasma-
activated liquid have been established extensively against bacteria, fungi, and viruses
(12–14, 16, 17), and the modes of their actions include membrane and lipid peroxida-
tion, protein oxidation, and DNA damage (12–17). It has been shown that RONS from
gas plasma can be designed to be selective against microbes with little harm to the
mammalian host (18, 19). The use of gas plasma for disinfection is inspired by the use
of endogenous ROS by immune cells of a mammalian host to inactivate invading
bacteria (12, 13).
As gas plasma endows its antimicrobial properties to its treated water (20), we
developed a saline-based gas plasma-activated disinfectant (PAD) as a novel catheter
lock solution. The aim of the current study was to determine the efficacy of PAD against
bacteria and fungi in a catheter biofilm model and to assess the effect of PAD on
primary human umbilical vein endothelial cells (HUVECs) as an in vitro model of blood
vessel endothelium. In doing so, we used the PAD as a novel antibiotic-antiseptic lock
solution.
RESULTS
Transient reactive oxygen and nitrogen species. Diverse reactive oxygen and
nitrogen species in PAD were observed, with all long-lived RONS at a low concentration,
with peak values at 10 to 300 M (Fig. 1). The peak concentration of a given reactive
species in PAD was markedly below the MIC of the species when acting alone. For
example, the MICs of H2O2 and ONOO are both 1 to 10 mM for E. coli (21, 22), and
these are approximately 3 orders of magnitude above the peak concentrations of H2O2
(10 M) and spin-trap adducts of ONOO (7 M) found in PAD (Fig. 1). Figure 1 shows
half-lives of 30 to 45 min for H2O2, NO2, and ONOO, as well as plasma-induced
acidification (pH 3), with which the main reactive chlorine species was hypochlorous
acid (HOCl) below 100 nM in air plasma-activated saline of greater than 1 mm in
thickness (23), 3 orders of magnitude below its MIC of approximately 12.5 M against
Staphylococcus aureus (24). Peak concentrations of NO2 (30 M) and NO3 (300 M)
were much lower than their MICs (0.5 mM for NO2 and 10 mM for NO3) (25) and
cytotoxicity dose (18 mM for NO3) (26). Together, antimicrobial reactive species in
PAD were at least 3 orders of magnitude below their individual MICs and were
FIG 1 (A) End view of an atmospheric air plasma generated on the surface of its hexagon-shaped mesh
electrode on a glass slide (in black), with each hexagon metal rim confining one surface discharge plasma
(in purple). The air plasma was sustained at a peak-to-peak voltage of 9.4 kV at 23 kHz and a dissipated
power density of 3.2 W. (B) A side view schematic of the surface plasma being used to treat 5 ml normal
saline in a petri dish downstream from the electrode for 2 min. The resulting PAD was then stored in a
sterile syringe. (C) Concentrations of H2O2, NO2, NO3, and spin-trap adducts of ONOO as well as a pH
of PAD at 37°C as a function of time after plasma activation of saline.
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transient, with H2O2, NO2, and ONOO half-lives of 30 to 45 min. Fundamentally
distinct from antibiotics, PAD is characterized by chemical diversity of many RONS, each
at low concentrations and decaying rapidly within 1 h.
Antimicrobial and antibiofilm efficacy. From an initial microbial load of 107 to 108
CFU/ml, the PAD lock eradicated 24-h luminal biofilms of methicillin-resistant S. aureus
(MRSA) (BAA-1707) and Pseudomonas aeruginosa (BAA-47) within 30 min and Candida
albicans 14053 within 45 min (Table 1). Complete suppression of regrowth in the
segment lumens was confirmed at 24 h after an extended lock of 45 min for bacteria
and 60 min for C. albicans (Table 1). However, the treatment with M-EDTA-25E (3 mg/ml
minocycline hydrochloride and 30 mg/ml EDTA mixed in 25% ethanol) left a residual
bacterial population of 3.0 to 3.5 log10 CFU/ml with a 30-min incubation and a residual
fungal population of 3.5 log10 CFU/ml with a 60-min incubation (Table 1). Furthermore,
24-h incubation of segment lumens treated with M-EDTA-25E lock solution for 60 min
led to recovery of P. aeruginosa and C. albicans, both to approximately 4.4 log10 CFU/ml
(Table 1). Against clinical isolates, PAD lock for 60 min led to a 6- to 8-log reduction of
all bacterial and fungal test microorganisms (Table 2) and complete suppression of
regrowth (Table 2). The same 60-min exposure to M-EDTA-25E lock solution resulted in
approximately 2.8 log10 CFU/ml of MRSA and Staphylococcus epidermidis and 4.3 log10
CFU/ml of C. albicans in segment lumens (Table 2). Microbial recovery with M-EDTA-25E
reached the initial luminal inoculum of 7 to 9 log10 CFU/ml (Table 2).
A detailed comparison between PAD and M-EDTA-25E was made for eradication and
regrowth of C. albicans 14053, with extended lock times of up to 360 min. Complete
regrowth inhibition of C. albicans biofilm required 360 min with M-EDTA-25E, while a
lock time of 60 min was needed for PAD (Table 3). Efficacy with 60-min PAD lock
solution was confirmed against 48-h biofilms tested against microbes listed in Table 1
(data not shown).
To confirm effective biofilm dispersal, Fig. 2A shows that 60-min exposure to PAD
removed adhesive materials from inoculated glass slides with MRSA BAA-1707 and C.
albicans 14053. In contrast, M-EDTA-25E exposure for 60 min led to considerable
TABLE 1 Survivors and regrowth of ATCC-derived isolates following PAD treatmenta
Lock solution
Lock time
(min)
Survivor population (log10 CFU/ml  SD) Regrowth population (log10 CFU/ml  SD)
MRSA
BAA-1707
P. aeruginosa
BAA-47
C. albicans
14053
MRSA
BAA-1707
P. aeruginosa
BAA-47
C. albicans
14053
Untreated 0 7.97 0.04 7.95 0.03 6.92 0.23 8.71 0.09 9.05 0.02 8.24 0.09
Saline 60 7.58 0.07 7.70 0.07 6.56 0.09 7.33 0.08 7.95 0.04 7.97 0.07
M-EDTA-25E 15 5.30 0.01 5.44 0.04 4.80 0.36 5.62 0.05 6.24 0.15 7.44 0.13
30 3.46 0.10 2.97 0.17 4.08 0.18 5.48 0.02 6.14 0.14 6.66 0.28
45 1 1.76 0.44 3.87 0.15 1 6.18 0.10 4.88 0.03
60 1 1 3.47 0.23 1 4.39 0.02 4.43 0.04
PAD 15 4.91 0.11 3.92 0.43 4.90 0.35 3.13 0.10 6.40 0.07 6.76 0.05
30 1 1 3.21 0.26 1 6.27 0.22 3.69 0.09
45 1 1 1 1 1 1.91 0.16
60 1 1 1 1 1 1
aFor all strains, P  0.001 compared with the control (n  3); detection limit, 1 log10 CFU/ml.
TABLE 2 Survivors and regrowth of clinical isolates following PAD treatmenta
Lock Solution
Lock time
(min)
Survivor population (log10 CFU/ml  SD) Regrowth population (log10 CFU/ml  SD)
MRSA SO385
S. epidermidis
M0881
C. albicans
P57072 MRSA SO385
S. epidermidis
M0881
C. albicans
P57072
Untreated 0 8.51 0.17 7.37 0.13 6.64 0.22 9.35 0.07 9.40 0.13 7.45 0.16
Saline 60 6.66 0.07 5.10 0.16 5.62 0.12 9.10 0.22 8.82 0.27 7.42 0.12
M-EDTA-25E 30 5.59 0.19 3.61 0.12 4.93 0.13 8.93 0.10 9.03 0.15 7.25 0.17
60 2.93 0.20 2.84 0.27 4.34 0.34 8.83 0.14 8.53 0.08 7.21 0.22
PAD 30 2.67 0.16 2.47 0.25 3.01 0.33 8.94 0.16 7.84 0.26 6.55 0.24
60 1 1 1 1 1 1
aFor all strains, P  0.05 compared with the control (n  3); detection limit, 1 log10 CFU/ml.
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biomass remaining on glass slides (Fig. 2A). To confirm biofilm dispersal from catheter
lumens, adhesive materials stained with crystal violet and dissolved from test lumens
with ethanol were quantified with optical absorption at 590 nm. Results are shown in
Fig. 2B and suggest that PAD exposure for 60 min reduced the optical absorption to
approximately 1% compared to approximately 41% achieved with M-EDTA-25E.
Cytotoxicity to primary human cells. Figure 3 shows that a simulated spill of PAD
minimally affected the viability of HUVECs at all evaluation points of 0.5, 2, 15, and 24 h. For
the lock-to-medium ratio at both 0.1% and 0.5%, there was no statistically significant
difference in the viability between treated and untreated HUVECs at 24 h, suggesting
TABLE 3 PAD and M-EDTA-25E efficacy at different lock dwell times against C. albicans
Lock time (min)
C. albicans 14053 populationa (log10 CFU/ml  SD)
M-EDTA-25E PAD
Survivors Regrowth Survivors Regrowth
0 7.25 0.23 8.13 0.27 7.25 0.23 8.13 0.27
30 5.89 0.25 8.03 0.22 5.25 0.13 6.87 0.19
60 4.87 0.11 6.60 0.17 1 1
120 4.34 0.13 6.20 0.32 1 1
180 2.60 0.28 5.90 0.30 1 1
240 1 4.30 0.27 1 1
300 1 2.99 0.25 1 1
360 1 1 1 1
aFor all conditions, P  0.001 compared with the control (n  3); detection limit, 1 log10 CFU/ml.
FIG 2 (A and B) Microscopic views of the biofilm formation in glass chambers after crystal violet (CV)
staining (lens magnification, 100) (A) and quantification of CV (B). P  0.005 (***) and P  0.01 (**)
compared with the control. The scale bar is 20 m.
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an effective repair of initial minor injuries in PAD-treated human cells. In contrast, the
same amount of spilled M-EDTA-25E damaged HUVECs, with cell viability clearly lower
at the lock-to-medium ratio of 0.5% than 0.1%. Viability of HUVECs treated with
M-EDTA-25E became progressively decreased with incubation time, suggesting an
accumulation of unrepaired injury. For the case of 24-h incubation when necessary
repairs of cellular damage should have taken place, cell viability was 59% for M-EDTA-
25E at the lock-to-medium ratio of 0.5%, suggesting cell death.
PAD effects on silicon catheter surface morphology. To test if the RONS in
acidified PAD (Fig. 1) affects the catheter material after repeated PAD locking, we
performed an accelerated aging test by continuously locking segments of catheter
tubing for 7 days with regularly replenished PAD. In practice, PAD locking for 2 h per
day is sufficient to ensure complete suppression of microbial regrowth (Tables 1 and 2).
There was no evidence of any episodes of fissures, cracks, or other morphological
abnormalities in PAD-treated catheter tubes (Fig. 4). When the test was repeated for
polyurethane for 7 days, no evidence of any morphological abnormalities was found
from scanning electron microscope (SEM) micrographs (data now shown).
DISCUSSION
Our study demonstrates that PAD lock solution is effective against microbial biofilms
implicated in CRBSI with minimal cytotoxicity to primary human vein epithelial cells.
Exposure to PAD lock for 60 min led to a reduction of viable bacterial and fungal biofilms
of 6 to 8 orders of magnitude and completely suppressed their regrowth. Similarly, PAD
lock exposure for 60 min substantially reduced all adherent matter on glass slides inocu-
lated with MRSA or C. albicans. For C. albicans 14053, M-EDTA-25E required 6 h to achieve
similar eradication and regrowth suppression. This is broadly in line with the capability of
current ALT that generally requires prolonged lock times (27, 28).
Variable efficacy has been reported for current ALT and antifungal lock therapy
(AfLT) (27, 28). For PAD therapy, effective lock times were approximately 60 min against
the Gram-positive and Gram-negative bacteria as well as C. albicans, which we studied
(Tables 1 and 2 and Fig. 2). This suggests that PAD therapy can be applied prior to
FIG 3 Evaluation of potential cytotoxic activity after exposure to HUVECs by leaked lock solution at
solution-to-medium ratios of 0.1% and 0.5%. n  3. P  0.01 (**) and P  0.05 (*) compared with the
control. NS, not significant.
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identification of pathogens that may be involved in a suspected CRBSI episode. The
broad-spectrum antimicrobial properties of PAD are based on chemical diversity of
reactive oxygen, nitrogen, and chlorine species (29) and collectively are capable of
attacking different cellular targets (14, 15) with minimal risk of systemic toxicity (Fig. 3)
or damage to silicone catheters (Fig. 4).
An additional advantage of PAD is that we found minimal toxicity upon exposure to
primary human umbilical vein endothelial cells. This is likely benefited from pulsed
RONS of PAD (Fig. 1), with which oxidative stresses to HUVECs are transient and as such
are more easily repaired than chemicals that generate reactive oxygen species in living
tissues for many months (39). Furthermore, continuous PAD locking for 7 days did not
result in any morphological abnormalities of silicone, such as fissures, cracks, or damage
when imaged using SEM (Fig. 4). The maximum daily exposure of a CVC to PAD is 2 h,
and as such the impact of continuous PAD locking for 7 days would be equivalent to
that of 2-h daily PAD therapy on an indwelling CVC for 84 hospital days [i.e., (7 24)/2].
PAD production and utility in the hospital setting is readily feasible with a table-top
automated PAD-making machine having a footprint of 6 by 12 inches.
Potential limitations to this study are the limited number of microbes included and
the facts that studies were not carried out in plasma or serum, only silicone material
was tested, and additional testing was not performed to assess the impact of our PAD
lock solution on the silicone tubes (e.g., testing the modulus of elasticity, force at break,
and maximum stress at break).
PAD lock solution is free of antibiotics, and the mechanism of action does not
involve specific binding sites on bacteria or fungi, thereby minimizing the risk of
selecting for antimicrobial resistance (11). In this context, it is interesting that a 2-h
exposure to a non-antibiotic-containing, nitroglycerin-based lock solution reduces
bacterial and fungal intraluminal biofilms by 4 orders of magnitude (30, 31). Nitroglyc-
erin produces reactive oxygen and nitrogen species (32), and this may explain why its
activity against bacteria and fungi is of similarly broad spectrum to PAD. The high
activity of PAD in both bacteria and fungi is associated, at least partly, with its chemical
diversity (Fig. 1C) and their multiple cellular targets, including lipid peroxidation,
FIG 4 SEM micrographs (25,000 magnification) of the luminal surface of silicone catheter tubing seg-
ments with the tubing segments as received from the manufactured (A), stored for 7 days at 37°C with no
treatment (B), and treated with saline (C) or PAD (D) for 7 days at 37°C.
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protein oxidation, and DNA damage (12–17). Recent evidence of DNA-protein cross-
links in gas plasma-treated bacteria highlights the challenge for microbes to enable
effective repair after plasma treatment (33). This lends further support to the superior
activity of PAD. Taking these results together, PAD lock therapy may be an innovative
addition to current ALT and AfLT.
MATERIALS AND METHODS
Catheter lock solutions. Minocycline hydrochloride (3 mg/ml) and EDTA (30 mg/ml) were mixed in
25% ethanol (M-EDTA-25E) as a comparator lock solution (34). PAD was formed by treating 5 ml of
normal saline (NaCl) for 2 min with a room temperature gas plasma system at 3.2 W in ambient air (Fig.
1) (39). For results presented here, PAD usually was used within 5 min after its production. Untreated
saline was used as a control.
Microorganisms and luminal biofilm model.MRSA BAA-1707, P. aeruginosa BAA-47, and C. albicans
14053 (ATCC, Manassas, VA) were used to test antimicrobial efficacy of PAD. Additionally, PAD was tested
with clinical isolates of MRSA (SO385), S. epidermidis (M0881), and C. albicans (BEI, Manassas, VA), as well
as a laboratory control strain of P. aeruginosa 27853 (ATCC, Manassas, VA). MRSA and S. epidermidis were
grown on Luria-Bertani (LB) agar, P. aeruginosa on brain heart infusion (BHI) agar, and C. albicans on
yeast-malt (YM) agar. A single colony was inoculated into 10 ml of appropriate broth, incubated
overnight at 37°C with shaking at 160 rpm, harvested at mid-logarithmic phase by centrifugation (500 
g, 5 min), and then washed twice with 1 phosphate-buffered saline (PBS). The inoculum concentration
was adjusted to 1.0  107 to 2.0  107 CFU/ml by broth dilution.
We modified a luminal biofilm model (4, 30) using sterile silicone tubing with an inner diameter of
1.58 mm and outer diameter of 3.175 mm (NewAge, Southampton, PA). Silicone tubing segments, 305
mm in length, were sterilized and inoculated with approximately 600 l of a prepared microbial culture
using a sterile syringe. Each inoculated catheter was sealed with a sterile, tight-fitting polytetrafluoreth-
ylene plug, placed in a sterile petri dish, and incubated without shaking for 24 or 48 h at 37°C. Inoculated
segments were gently flushed with normal saline, removing nonadherent microorganisms and leaving
intact biofilm.
Eradication and regrowth assays. In the eradication assay, 600 l of a test lock solution was slowly
injected into the lumen of each inoculated segment using a syringe. Segments were then incubated at
37°C for 15 to 360 min. After incubation, the external surface of each segment was thoroughly swabbed
with 70% (vol/vol) ethanol and allowed to air dry to ensure that only luminal microbes were recovered.
Luminal contents were removed with a gentle saline flush, and each segment was then cut into three
segments of 101.6 mm and submerged in 2 ml of 0.1 M glycine buffer (pH 7.0). Each of these segments
was then vortexed for 1 min, sonicated at 40 kHz for 1 min in a room temperature water bath, and then
vortexed for an additional minute. Luminal contents were then serially diluted and colony counts were
enumerated using a plate counter (detection limit, 10 CFU/ml).
To evaluate microbial regrowth, catheter segments from each eradication treatment were placed in
a sterile 15-ml Falcon tube filled with 2 ml of appropriate broth and incubated overnight with shaking
at 37°C. Following incubation, segments were vortexed for 1 min and then sonicated for 1 min. A 200-l
aliquot of sonicated broth was used for serial dilution and plating. Plates were incubated overnight at
37°C before colony enumeration.
Luminal biofilm dispersal assay. Before and after PAD treatment, biofilms on the inner walls of
catheter lumens were stained with 0.1% crystal violet (BD, Franklin Lakes, NJ) for 15 min at room
temperature. Unbound dyes were washed away, and the lumens were left in the hood to air dry. The
air-dried lumens were cut into three identical individual pieces and submerged in 2 ml of 95%
molecular-grade ethanol for 30 min. Crystal violet dyes were dissolved in ethanol and quantitated by
optical absorbance at 590 nm. Negative controls were uninfected catheter lumens. All experiments were
performed in triplicate.
Slide biofilm dispersal assay. Glass chamber slides (Thermo Fisher Scientific, Fair Lawn, NJ) were
inoculated with 500 l of microbial cultures at 1.0  107 to 2.0  107 CFU/ml and then incubated for 24 h
to form biofilm on the surface of the slides. To remove planktonic cells, the medium was aspirated off
and the biomass washed three times with 1 ml of 1 PBS. Following gentle washing, biofilms were
treated with 200 l of lock solution for 60 min. Before and after exposure to the lock solution, various
wells of the inoculated slides were stained with crystal violet (BD, Franklin Lakes, NJ) for imaging and
quantification of any adherent material (35).
Cytotoxicity assay. To assess for cytotoxicity of inadvertently spilled test lock solutions, we used
HUVECs (Lonza, Walkersville, MD) with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay using the Vybrant MTT cell proliferation assay kit (Invitrogen, CA, USA) according to the
manufacturer’s instructions. Briefly, HUVECs were seeded in endothelial basal medium (Lonza, Walkers-
ville, MD) at 200 l/well in 96-well plates at a density of 1.0  105 cells/ml 1 day prior to a cytotoxicity
test. To determine the volume of test lock solution to treat HUVECs, we used the algorithm that the
maximum lock solution escaping from a CVC is approximately 0.5 ml per event (36), and this solution is
distributed in the amount of blood pumped in 1 to 2 heart beats (37), which is approximately 100 ml in
a healthy adult. This corresponds to a lock solution/blood ratio of up to approximately 0.5% per spill.
Given this, each test lock solution was mixed at 0.1 to 0.5% of the cell medium in each HUVEC-containing
well of the 96-well plates. Untreated HUVECs served as controls. As it is very rare for current catheters to
allow for more than one spill event during one heart beat (36, 37), the lock solution-to-blood ratio of
Gas Plasma-Activated Catheter Lock Solution Antimicrobial Agents and Chemotherapy
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0.5% is likely to be the maximum even with multiple spills and represents the worst-case scenario. The
total catheter solution in our study was 0.6 ml in volume.
Measurements of reactive species. Long-lived RONS in PAD at 37°C were measured with a
microplate reader (FLUOStar, BMG Labtech, NC, USA) with the Amplex Red assay kit (Thermo Fisher
Scientific, MA, USA) for H2O2 and the Griess reagent assay (Cayman Chemical Co., MI, USA) for nitrite
(NO2) and nitrate (NO3). Similarly, short-lived RONS were measured at 37°C with an electron spin
resonance (ESR) spectrometer (EMX; Bruker, Germany) and spin traps (38). Specifically, DMPO (5,5-
dimethyl-1-pyrroline N-oxide) was used for trapping hydroxyl radicals (●OH), and DTCS (diethyldithio-
carbamate) and MGD (N-methyl-D-glucamine dithiocarbamate) were used for trapping nitric oxide (NO●)
(all from Dojindo Laboratories, Kumamoto, Japan). Superoxide (O2●) and peroxynitrite (ONOO) were
trapped using TEMPONE-H (1-hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine hydrochloride; from Enzo
Biochem, USA). The ESR detection limit was approximately 100 nM.
Surface characterization. Surface topology of the inner wall of silicone catheter tubing was
examined using a JSM-6060LV scanning electron microscope (SEM; JEOL, Japan). To mimic prolonged
exposure, tubing segments were locked with 600 l of PAD for 2 h at 37°C. Lock solutions then were
replenished with 600 l of freshly prepared PAD for another 2 h at 37°C. This was repeated 5 times
consecutively in a day. After the last 2-h treatment, test segments were locked with freshly prepared PAD
overnight (	14 h) at 37°C. The treatment procedure lasted 7 days. As controls, segments of silicone
tubing were locked with normal saline with the same procedure as that for lock solution replacement
and untreated segments were stored at 37°C, both for 7 days. Following the treatment, tubing segments
were cut open, and the inner surface of each segment was gold-coated and examined with an SEM at
a working voltage of 15 kV.
Statistical analysis. All test conditions were studied in at least three independent experiments. Data
are presented as means  standard deviations (SD). Student t test was used to determine significance
between data points.
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